Benitec Biopharma Files 8-K for Operations Update
Ticker: BNTC · Form: 8-K · Filed: Sep 26, 2024 · CIK: 1808898
Sentiment: neutral
Topics: operations, financial-condition, filing
TL;DR
Benitec Biopharma filed an 8-K on 9/26/24 for operational and financial updates.
AI Summary
Benitec Biopharma Inc. filed an 8-K on September 26, 2024, to report on its results of operations and financial condition, as well as to file financial statements and exhibits. The filing does not appear to contain specific financial figures or operational updates beyond the procedural nature of the report.
Why It Matters
This 8-K filing indicates that Benitec Biopharma is providing an update on its financial condition and operations, which is important for investors to monitor the company's status.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting operational and financial condition, without disclosing specific material events or changes.
Key Players & Entities
- Benitec Biopharma Inc. (company) — Registrant
- September 26, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 001-39267 (identifier) — Commission File Number
- 3940 Trust Way, Hayward, California 94545 (address) — Principal Executive Offices
- (510) 780-0819 (phone_number) — Registrant's Telephone Number
FAQ
What specific financial information is being reported in this 8-K?
The filing indicates it pertains to 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but specific figures are not detailed in the provided text.
When was the earliest event reported in this filing?
The earliest event reported was on September 26, 2024.
What is the principal executive office address for Benitec Biopharma Inc.?
The principal executive offices are located at 3940 Trust Way, Hayward, California 94545.
What is the Commission File Number for Benitec Biopharma Inc.?
The Commission File Number is 001-39267.
What is the SIC code for Benitec Biopharma Inc.?
The Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 565 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-09-26 16:43:00
Key Financial Figures
- $0.0001 B — ich registered Common Stock, par value $0.0001 BNTC The Nasdaq Stock Market LLC Indic
Filing Documents
- d817476d8k.htm (8-K) — 26KB
- d817476dex991.htm (EX-99.1) — 78KB
- g817476dsp5.jpg (GRAPHIC) — 10KB
- 0001193125-24-226999.txt ( ) — 244KB
- bntc-20240926.xsd (EX-101.SCH) — 3KB
- bntc-20240926_lab.xml (EX-101.LAB) — 17KB
- bntc-20240926_pre.xml (EX-101.PRE) — 11KB
- d817476d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release of Benitec Biopharma Inc. dated September 26, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BENITEC BIOPHARMA INC. Date: September 26, 2024 By: /s/ Jerel A. Banks Name: Jerel A. Banks Title: Chief Executive Officer